3,0
15 mag 2024
Dipendente attuale, più di un anno
Cambridge, East of England, England
Consiglia
Gradimento del CEO
Pronostico commerciale
Vantaggi
Really smart people Great facilities Interesting science
Svantaggi
Has been described as a passive-aggressive organisation which is very true - hard to get things done People generally unhappy and disengaged, due to low pay, high workloads and little transparency from upper management Not the most innovative of Big pharma - content to fast follow and acquire late stage assets once validated rather than invest in their own original R&D Hard to get promoted and unclear what is required to progress